Trimethylammonium

Trimethylammonium

SCHEMBL851475

CCN(CC)CC.CN(C)C

nearest known ligand 0.40

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.33
HRH3 Q9Y5N1 1/20 0.32
MGLL Q99685 1/20 0.31
CYP2C9 P11712 1/20 0.30
HPGD P15428 1/20 0.30
HSD17B10 Q99714 1/20 0.30
KDM4E B2RXH2 1/20 0.30
MEN1 O00255 1/20 0.30
POLB P06746 1/20 0.30
MAPT P10636 1/20 0.30
THRB P10828 1/20 0.30
APEX1 P27695 1/20 0.30
MAPK1 P28482 1/20 0.30
HTT P42858 1/20 0.30
RECQL P46063 1/20 0.30
CACNA1B Q00975 1/20 0.30
APBA1 Q02410 1/20 0.30
KMT2A Q03164 1/20 0.30
MCL1 Q07820 1/20 0.30
HKDC1 Q2TB90 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trimethylammonium SCHEMBL27926974 0.95 ALDH1A1 (0.31) ALDH1A1HRH3
Trimethylammonium SCHEMBL28160753 0.95 ALDH1A1 (0.31) ALDH1A1HRH3
Trimethylammonium SCHEMBL21110533 0.95 ALDH1A1 (0.31) ALDH1A1HRH3
Trimethylammonium SCHEMBL28160752 0.95 ALDH1A1 (0.31) ALDH1A1HRH3
SCHEMBL1736341 0.89 ALDH1A1 (0.40) ALDH1A1HRH3MGLLCYP2C9HPGD
SCHEMBL30 0.89
SCHEMBL124190 0.89
N,N-Dimethylethanaminium SCHEMBL4164622 0.86 ALDH1A1 (0.31) ALDH1A1HRH3
Trimethylammonium SCHEMBL25409740 0.84 ALDH1A1 (0.31) ALDH1A1CYP2C9HPGDHSD17B10
Water SCHEMBL20920097 0.84 ALDH1A1 (0.36) ALDH1A1HRH3MGLLCYP2C9HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 145 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10023683-B2 Catalyst compositions for improving polyurethane foam performance EVONIK DEGUSSA GMBH (DE) 2018-07-17 US claimed
CN-107858178-A A kind of oil emulsion of Effictive nuisancelless and preparation method thereof 深圳市国能环保科技有限公司 2018-03-30 CN claimed
US-20160272594-A1 PREPARATION METHOD OF DEXMEDETOMIDINE INTERMEDIATE TIANJIN WEIJIE PHARMACEUTICAL CO., LTD (CN) 2016-09-22 US claimed
US-20080319200-A1 PROCESS FOR PREPARING OXAZOLINE-PROTECTED AMINODIOL COMPOUNDS USEFUL AS INTERMEDIATES TO FLORFENICOL SCHERING-PLOUGH ANIMAL HEALTH CORP. 2008-12-25 US claimed
EP-0252637-A2 Composition for the adhesive activation of polymeric material, process for treating polymeric material with an adhesive activating composition and the polymeric material thus activated CELANESE CORPORATION (US) 1988-01-13 EP claimed
US-3993646-A Process for the ring expansion of penicillins to cephalosporin compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JA) 1976-11-23 US claimed
US-11678958-B2 Fabrication of dental appliances ArchForm Inc. (US) 2023-06-20 US disclosed
US-11661416-B2 Method for isolation of a dianhydride and dianhydrides prepared by the method SHPP GLOBAL TECHNOLOGIES B.V. (NL) 2023-05-30 US disclosed
CN-112063353-B Polyurethane hot melt adhesive and preparation method thereof 广州市白云化工实业有限公司 2022-09-09 CN disclosed
US-11365125-B2 Supercritical drying method for silica wet gel blanket LG CHEM, LTD. (KR) 2022-06-21 US disclosed
CN-111909337-B Crosslinking agent, polyurethane prepolymer and single-component polyurethane adhesive 广州市白云化工实业有限公司 2022-04-26 CN disclosed
EP-3981772-A1 TETRA-FUNCTIONAL CHEMICAL PROBE AND METHOD FOR IDENTIFYING TARGET MEMBRANE PROTEIN FROM LIVING CELL OR LIVING TISSUE BY USING SAID PROBE Otsuka Pharmaceutical Co., Ltd. (JP) 2022-04-13 EP disclosed
US-20210246124-A1 METHOD FOR ISOLATION OF A DIANHYDRIDE AND DIANHYDRIDES PREPARED BY THE METHOD SHPP GLOBAL TECHNOLOGIES B.V. (NL) 2021-08-12 US disclosed
EP-0043546-B1 7-OXO-CEPHALOSPORINS AND 6-OXO-PENICILLINS, THEIR ANALOGUES AND PROCESS FOR THEIR PREPARATION FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1986-01-29 EP disclosed
US-4511683-A ANIONIC SURFACTANTS JAPAN SYNTHETIC RUBBER CO., LTD. (JP) 1985-04-16 US disclosed
US-4426519-A ANTIBIOTICS ROUSSEL UCLAF (FR) 1984-01-17 US disclosed
EP-0008796-B1 POLYPHOSPHAZENE POLYMERS CONTAINING ALKOXY SUBSTITUENTS CONTAINING A FULLY SUBSTITUTED CARBON IN THE BETA POSITION AND PROCESS FOR THEIR PREPARATION THE FIRESTONE TIRE & RUBBER COMPANY (US) 1982-03-24 EP disclosed
US-4299945-A HEAT POLYMERIZATION OF AN AROMATIC DIAMINO COMPOUND AND AN AROMATIC TRIBASIC CARBOXYLIC ACID TORAY INDUSTRIES, INC. (JP) 1981-11-10 US disclosed
EP-0007156-A1 Carbamates, compositions containing them, their insecticidal and nematocidal use, and a method for their preparation E.I. DU PONT DE NEMOURS AND COMPANY (US) 1980-01-23 EP disclosed
US-3932550-A DIMERIZATION OF ISOPRENE, COORDINATION CATALYST MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JA) 1976-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210246124-A1 METHOD FOR ISOLATION OF A DIANHYDRIDE AND DIANHYDRIDES PREPARED BY THE METHOD DDC, APEH, DNPEP ALDH1A1 2859/4885HRH3 377/4885MGLL 4218/4885
US-20080319200-A1 PROCESS FOR PREPARING OXAZOLINE-PROTECTED AMINODIOL COMPOUNDS USEFUL AS INTERMEDIATES TO FLORFENICOL PFAS, DHFR, DDC ALDH1A1 898/4885HRH3 1412/4885MGLL 2006/4885
US-20160272594-A1 PREPARATION METHOD OF DEXMEDETOMIDINE INTERMEDIATE AVPR2, TET1, TET2 ALDH1A1 852/4885HRH3 96/4885MGLL 582/4885
US-11661416-B2 Method for isolation of a dianhydride and dianhydrides prepared by the method DDC, APEH, DNPEP ALDH1A1 2859/4885HRH3 377/4885MGLL 4218/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.